Novartis AG

NOVN

CH0012005267

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).

Employees

76,057

Sector

Pharmaceuticals

Calendar

2024-12-07 - American Society of Hematology Meeting - Abstract Number - 67

More about the company

Income Statement and Estimates

income-statement-evolution-chart NOVARTIS-AG

More financial data

Analysis / Opinion

NOVARTIS : Q3 beat and a guidance upgrade; today’s dip is a buying opportunity

October 29, 2024 at 02:16 pm EDT

Vas Narasimhan, CEO of Novartis: 40% margin by 2027

April 23, 2024 at 07:18 am EDT

Novartis AG : Sandoz takes its first steps on the stock exchange

October 04, 2023 at 10:32 am EDT

More Strategies

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

102.79USD

Average target price

115.73USD

Spread / Average Target

+12.59%

Consensus

Profit revisions

Estimate revisions

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Swiss Exchange Other stock markets 11:31:52 2024-12-05 am EST			5-day change	1st Jan Change
90.38 ^CHF	+0.31%		-3.21%	+6.49%

Dec. 05	NOVARTIS AG : Deutsche Bank remains Neutral	ZD
Dec. 05	US Court Rejects Novartis' Appeal to Block Heart Failure Drug's Generic Version	MT

NOVARTIS AG : Deutsche Bank remains Neutral	Dec. 05	ZD
US Court Rejects Novartis' Appeal to Block Heart Failure Drug's Generic Version	Dec. 04	MT
Novartis cannot block generic of best-selling heart drug, US appeals court says	Dec. 04	RE
HSBC Downgrades Novartis to Reduce, Price Target is $95	Dec. 04	MT
NOVARTIS AG : JP Morgan reiterates its Neutral rating	Dec. 03	ZD
Sector Update: Health Care Stocks Slipping Late Afternoon	Dec. 02	MT
Sector Update: Health Care Stocks Softer Monday Afternoon	Dec. 02	MT
Sector Update: Health Care	Dec. 02	MT
PTC Therapeutics Strikes Up to $2.9 Billion Licensing Deal With Novartis for Huntington's Disease Drug Candidate	Dec. 02	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Monday	Dec. 02	MT
Sector Update: Health Care	Dec. 02	MT
Novartis AG, PTC Therapeutics, Inc. - M&A Call	Dec. 02
Olema Partners With Novartis for Clinical Trial of Potential Breast Cancer Drug, Launches $250 Million Stock, Warrant Placement	Dec. 02	MT
PTC Therapeutics Shares Jump on Pact With Novartis	Dec. 02	DJ
PTC Therapeutics Signs Exclusive Global License Deal With Novartis Unit for PTC518 Huntington's Disease Program; Shares Rise Premarket	Dec. 02	MT
Swiss Market Index Recovers; Nestlé Shares Edge Up	Nov. 27	MT
Global markets live: HP, Dell, Amazon, EasyJet, HSBC...	Nov. 27
Novartis Receives European Commission Approval for Adjuvant Early Breast Cancer Treatment	Nov. 27	MT
Novartis Wins EU Approval for Expanded Use of Kisqali in Breast Cancer Treatment	Nov. 27	MT
Novartis: has received authorization from the European Commission	Nov. 27	CF
Novartis' Early Breast Cancer Drug Gets Approval from EU Commission	Nov. 27	MT
EU Commission Approves Novartis' Kisqali in Broad Population of Breast Cancer Patients	Nov. 27	MT
Novartis Kisqali(R) receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence	Nov. 27	DJ
Novartis Kisqali Receives European Commission Approval in A Broad Population of Patients with HR+/HER2- Early Breast Cancer at High Risk of Recurrence	Nov. 27	CI
Octavian AG Lifts Price Target on Novartis, Maintains Hold Recommendation	Nov. 26	MT

Novartis AG

Equities